Covid-19 cells and red blood cells
Human challenge trial launches to study immune response to COVID-19

Image credit: Shutterstock

Human challenge trial launches to study immune response to COVID-19

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Researchers at the University of Oxford have launched a human challenge trial to look at what kind of immune response can stop people from becoming re-infected. They also want to see how the immune system reacts second time round. A human challenge trial in medical research is a carefully controlled study that involves purposefully infecting a subject with a pathogen or bug, in order to study the effects of that infection.

The study will take place in two phases with different participants in each phase. The first phase, which will start in April 2021, will establish the lowest dose of virus which, in approximately 50% of people who have previously been naturally infected, can take hold and start replicating but produce little or no symptoms. In the second phase of the study, expected to start in summer 2021, all participants will be infected with the standardised dose of virus which was established in phase one.

For phase one, up to 64 healthy participants between the ages of 18 – 30 who have previously been naturally infected with COVID-19 will be re-exposed to the virus in carefully controlled conditions. 

Phase one will have two groups, one (of 24) that will get increasing dose amounts until the optimal dose is found and a second (of 10 - 40) who will then get the optimal dose.

The virus used in the study will be the original strain from Wuhan, China. The participants will be quarantined in a specially designed hospital suite for a minimum of 17 days under the care of the research team. They will undergo numerous medical tests including CT scans of the lungs and MRI scans of the heart. The risks to participants will minimised by making sure that those who take part are completely fit and well and have completely recovered from their first infection with COVID.

Any participants who develop any symptoms will be given medical treatment with the Regeneron monoclonal antibody treatment. They will only be discharged from the quarantine unit when they are no longer infected and not at risk of infecting others. The full length of the study will be 12 months, including a minimum of eight follow-up appointments after discharge. Participation in the study is completely voluntary.

Helen McShane, Professor of Vaccinology at the Department of Paediatrics, University of Oxford and Chief Investigator on the study said, ‘Challenge studies tell us things that other studies cannot because, unlike natural infection, they are tightly controlled. When we re-infect these participants, we will know exactly how their immune system has reacted to the first COVID infection, exactly when the second infection occurs, and exactly how much virus they got. As well as enhancing our basic understanding, this may help us to design tests that can accurately predict whether people are protected.

‘In phase two, we will explore two different things. First, we will define very carefully the baseline immune response in the volunteers, before we infect them. We will then infect them with the dose of virus chosen from the first study and measure how much virus we can detect after infection. We will then be able to understand what kind of immune responses protect against re-infection. Second, we will measure the immune response at several time points after infection so we can understand what immune response is generated by the virus.

‘A challenge study allows us to make these measurements very precisely because we know exactly when someone is infected. The information from this work will allow us to design better vaccines and treatments, and also to understand if people are protected after having COVID, and for how long.’

The study is funded by the Wellcome Trust. Shobana Balasingam, Vaccines Senior Research Advisor at Wellcome, said, ‘There are still many unknowns surrounding this virus and human infections studies can enable us to learn a lot about Covid-19. This study has the potential to transform our understanding by providing high-quality data on how our immune system responds to a second infection with this virus.

‘The findings could have important implications for how we handle Covid-19 in the future, and inform not just vaccine development but also research into the range of effective treatments that are also urgently needed. Keeping up the pace of scientific research and development, through crucial studies such as this remain the only way we will truly get ahead of this pandemic and bring it under control.’